Navigation Links
MabPlex International, Ltd. Opens New Phase III and Commercial Manufacturing Facility
Date:12/10/2018

MabPlex International, Ltd., a fully integrated Contract Development and Manufacturing Organization (CDMO) with sites in China and the United States, providing comprehensive (cell line) development, process characterization, conjugation optimization, cGMP manufacturing, and aseptic fill finish solutions for monoclonal antibody (mAb) and antibody-drug conjugate (ADC) therapeutics, announced the grand opening and ribbon-cutting ceremony for their new M2 manufacturing facility in Yantai, China. The opening ceremony took place on September 6, 2018.

This milestone will enhance MabPlex’s ability to deliver Phase III and commercial development and manufacturing solutions to clients in multiple global markets and expand the company's manufacturing operations to a total of approximately 750,000 ft²; with 400,000 ft² devoted specifically to cGMP execution.

The completed 'M2' facility includes six independent cell culture suites, four independent purification suites, and a cGMP warehouse. Each of the six cell culture suites will support up to two single-use bioreactors at volumes of up to 2,000L (with a maximum capacity of 24,000L).

"With a growing number of novel and increasingly complex drug constructs in early development pipelines and new targeted therapies, such as ADCs, in late stage development and moving to commercialization, there is a growing global demand for specialized CDMOs," said Jianmin Fang, Ph.D, Chairman and CEO of MabPlex International, Ltd.

The new facility was built in response to the growing, global, demand for biomanufacturing capacity and complies with all international manufacturing regulations.

“This new facility, along with the opening of our San Diego and Shanghai process development sites, will increase our capacity to meet the needs of our new and current clients as they progress to commercialization,” Fang added.

Earlier this year, MabPlex USA, a subsidiary of MabPlex International, Ltd., opened the company's new state of the art Process Development Center of Excellence located in La Jolla, CA (USA) near San Diego, CA (USA) with scale up capacity to 200L, offering world class expertise supporting cell line development, upstream and downstream process development, Antibody-drug Conjugate (ADC) development, analytical development and formulation development.

About MabPlex
MabPlex International, Ltd. was founded in 2013 and specializes in providing complete biologics development and manufacturing solutions. Our technical expertise allows us to provide effective solutions for monoclonal antibody and Antibody-drug Conjugate (ADC) therapeutics, from cell line development and process characterization, to conjugation optimization and cGMP manufacturing. MabPlex is committed to delivering quality solutions to our customers around the world.

Read the full story at https://www.prweb.com/releases/mabplex_international_ltd_opens_new_phase_iii_and_commercial_manufacturing_facility/prweb15976947.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. Yongye International, Inc. Announces Common Stock Will Resume Trading on the NASDAQ Stock Market on June 17, 2013
2. GeneCell International, Miami’s Preferred Cord Blood Laboratory, is Pleased to Announce That July is National Cord Blood Awareness Month
3. Miami’s Preferred Cord Blood Laboratory, GeneCell International, Partakes in North Shore Medical Center and Hialeah Hospital’s OB/GYN Symposium
4. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
5. Vet-Stem, Inc. Proudly Announces Distribution Agreement with Animal Health International, Inc. for Regenerative Cell Therapies
6. Beautiful You Magazine Features Nerium International, Creator of Best-Selling NeriumAD Age-Defying Treatment
7. Phenolic Resin Industry (International, China) Development Policy and Plan Now Available at ReportsnReports.com
8. Vital Force Technology, a Division of Energy Tools International, Focuses on Manufacturers with New Product Services and Marketing Campaigns
9. NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations
10. Fujifilm Holdings to Acquire Cellular Dynamics International, Inc.
11. Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2019)... ... May 30, 2019 , ... Object Pharma, ... the strategic acquisition of Metabiologics, Inc., a globally recognized leader in the production ... and commercialization rights to a full spectrum of botulinum neurotoxins, as well as ...
(Date:5/22/2019)... ... May 22, 2019 , ... Artemis (formerly Agrilyst), the leading enterprise ... funding round co-led by Astanor Ventures and Talis Capital with ... iSelect Fund . The company has raised $11.75m to date and will use ...
(Date:5/15/2019)... ... May 15, 2019 , ... Milton Hershey School® has ... for his work within the biomedical industry, where he is changing lives by creating ... , “William Harding epitomizes the vision of our founders – Milton and Catherine ...
(Date:5/14/2019)... , ... May 13, 2019 , ... ... helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging ... website. The redesigned website aims to improve LDA’s ability to communicate directly with ...
Breaking Biology Technology:
(Date:5/23/2019)... ... May 23, 2019 , ... ... for sales and service organizations, today announced its inclusion in DMG Consulting’s ... as the intelligent virtual agent (IVA) market share leader, based on number of ...
(Date:5/21/2019)... ... 2019 , ... Experiential tourism, a trend encompassing culinary travel, cultural exploration and ... And according to a recent report by Skift, a media company for the ... more travelers are wanting their journeys to be authentic and unique, and good cuisine ...
(Date:5/21/2019)... ... May 20, 2019 , ... Dr. David Greene , Founder and CEO ... Cell Therapy: Biotechnology to the Rescue, was produced by Award Winning filmmaker Dr. Elliott ... in regards to the safety of the procedures along with the potential for helping ...
Breaking Biology News(10 mins):